Maple Capital Management Inc. Has $13.65 Million Stock Position in Zoetis Inc. $ZTS

Maple Capital Management Inc. grew its stake in Zoetis Inc. (NYSE:ZTS) by 1.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,552 shares of the company’s stock after buying an additional 1,634 shares during the period. Maple Capital Management Inc.’s holdings in Zoetis were worth $13,654,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Lindbrook Capital LLC grew its holdings in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock valued at $612,000 after purchasing an additional 65 shares during the last quarter. Scott & Selber Inc. increased its stake in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after purchasing an additional 67 shares during the period. Secure Asset Management LLC lifted its position in shares of Zoetis by 2.9% during the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares during the last quarter. Moment Partners LLC boosted its stake in Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares during the period. Finally, CVA Family Office LLC grew its stake in shares of Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after acquiring an additional 74 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.3%

Shares of ZTS opened at $120.09 on Wednesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market cap of $52.92 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 2.31 and a beta of 0.90. The stock has a fifty day moving average price of $142.82 and a two-hundred day moving average price of $152.16. Zoetis Inc. has a 52-week low of $117.26 and a 52-week high of $181.85.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same period last year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZTS. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. JPMorgan Chase & Co. cut their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research decreased their price target on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Stifel Nicolaus set a $140.00 price objective on shares of Zoetis in a research note on Tuesday, November 4th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $180.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.